Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient (COMBAT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00826644 |
Recruitment Status :
Completed
First Posted : January 22, 2009
Last Update Posted : August 9, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I. The investigators will have a randomized prospective multicenter trial of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer.
Primary endpoints
- to assess Response Rate
Secondary endpoints
- to assess Overall response duration, Time to progression, Overall survival
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Carcinoma, Small Cell | Drug: Belotecan Drug: Etoposide Drug: Cisplatin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 147 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomized Prospective Multicenter Trial of Belotecan/Cisplatin Versus Etoposide/Cisplatin in Patients With Previously Untreated, Extensive-stage Small-cell Lung Cancer |
Actual Study Start Date : | January 2009 |
Actual Primary Completion Date : | February 2013 |
Actual Study Completion Date : | February 2013 |
Arm | Intervention/treatment |
---|---|
Experimental: Belotecan plus Cisplatin |
Drug: Belotecan
Belotecan : 0.5mg/㎡/day for Day 1 to 4, repeated every 3 weeks
Other Name: Camtobell Drug: Cisplatin Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks |
Active Comparator: Etoposide plus Cisplatin |
Drug: Etoposide
Etoposide 100mg/㎡/day for Day 1 to 3, repeated every 3 weeks Drug: Cisplatin Cisplatin 60mg/㎡/day for Day 1, repeated every 3 weeks |
- To assess the response Rate of Belotecan/Cisplatin versus Etoposide/Cisplatin in patients with previously untreated, extensive-stage small cell lung cancer [ Time Frame: two years ]
- to assess the overall response duration [ Time Frame: two years ]
- To assess the time to progression [ Time Frame: two years ]
- to assess the overall survival [ Time Frame: two years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 19 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- ECOG Performance status 0~2(those with performance status 2 must have been stable with no deterioration over the previous 2 weeks)
- Histologically or cytologically confirmed small cell lung cancer Patient without chemotherapy and radiotherapy
- Measurable lesion according to RECIST with at least one measurable lesion not previously irradiated, unless disease progression has been documented at that site
- Life expectancy of at least 3 months
- Provision of written informed consent
Exclusion Criteria:
- As judged by the investigator, any evidence of severe or uncontrolled systemic disease
- Serum bilirubin greater than 3 times the upper limit of reference range(ULRR)
- Aspartate aminotransferase (AST/SGOT) or alanine aminotransferase (ALT/SGPT)greater than 2.5 times ULN if no demonstrable liver metastases (or > 5 times in presence of liver metastases)
- Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study
- Pregnancy or breast-feeding women(women of child-bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy
- Evidence of brain metastasis
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00826644
Korea, Republic of | |
Chonnam National University Hwasun Hospital | |
Hwasun, Korea, Republic of, 58128 |
Principal Investigator: | In-Jae Oh, M.D.,Ph.D. | Chonnam National University Hospital |
Responsible Party: | In-Jae, Oh, MD, Assistant Professor, Chonnam National University Hospital |
ClinicalTrials.gov Identifier: | NCT00826644 |
Other Study ID Numbers: |
CSCLC-0810 |
First Posted: | January 22, 2009 Key Record Dates |
Last Update Posted: | August 9, 2021 |
Last Verified: | August 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Small cell lung cancer Camptothecin Response rate |
Lung Neoplasms Small Cell Lung Carcinoma Carcinoma, Small Cell Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Carcinoma |
Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Etoposide Belotecan Antineoplastic Agents Antineoplastic Agents, Phytogenic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Topoisomerase I Inhibitors |